A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement
Phase of Trial: Phase IV
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Infliximab (Primary) ; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms RECOVERY
- Sponsors Janssen Research & Development
- 30 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated